

Contents

Phosphodiesterase Inhibitors: History of Pharmacology	1
Christian Schudt, Armin Hatzelmann, Rolf Beume, and Hermann Tenor	
Phosphodiesterase Inhibitors: Factors That Influence Potency, Selectivity, and Action	47
Sharron H. Francis, Miles D. Houslay, and Marco Conti	
Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics	85
Hermann Tenor, Armin Hatzelmann, Rolf Beume, Gezim Lahu, Karl Zech, and Thomas D. Bethke	
Structural Insight into the Substrate Specificity of Phosphodiesterases	121
Hengming Ke, Huanchen Wang, and Mengchun Ye	
A Fission Yeast-Based Platform for Phosphodiesterase Inhibitor HTSs and Analyses of Phosphodiesterase Activity	135
Didem Demirbas, Ozge Ceyhan, Arlene R. Wyman, and Charles S. Hoffman	
The GAF-Tandem Domain of Phosphodiesterase 5 as a Potential Drug Target	151
Joachim E. Schultz, Torsten Dunkern, Elvira Gawlitta-Gorka, and Gabriele Sorg	
Small Molecule Allosteric Modulators of Phosphodiesterase 4	167
Mark E. Gurney, Alex B. Burgin, Olafur T. Magnusson, and Lance J. Stewart	
Regulation of Endothelial Barrier Function by Cyclic Nucleotides: The Role of Phosphodiesterases	193
James Surapisitchat and Joseph A. Beavo	

Phosphodiesterases as Targets for Intermittent Claudication	211
Yongge Liu, Yasmin Shakur, and Junichi Kambayashi	
Phosphodiesterase Inhibition in Heart Failure	237
Matthew A. Movsesian and Rakesh C. Kukreja	
Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary Hypertension	251
Kathryn N. Farrow and Robin H. Steinhorn	
Role of Phosphodiesterases in Adult-Onset Pulmonary Arterial Hypertension	279
F. Murray, M.R. MacLean, and P.A. Insel	
Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms by Phosphodiesterase Inhibitors	307
Stefan Ückert and Christian G. Stief	
Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the <i>mdx</i> Mouse Model of Duchenne Muscular Dystrophy	323
Justin M. Percival, Candace M. Adamo, Joseph A. Beavo, and Stanley C. Froehner	
Phosphodiesterases as Targets for Modulating T-Cell Responses	345
Elisa Bjørgo, Kristine Moltu, and Kjetil Taskén	
Cyclic Nucleotides and Phosphodiesterases in Monocytic Differentiation	365
Angie L. Hertz and Joseph A. Beavo	
Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases	391
C.P. Page and D. Spina	
Harnessing the Clinical Efficacy of Phosphodiesterase 4 Inhibitors in Inflammatory Lung Diseases: Dual-Selective Phosphodiesterase Inhibitors and Novel Combination Therapies	415
Mark A. Giembycz and Robert Newton	
Phosphodiesterases in the Central Nervous System: Implications in Mood and Cognitive Disorders	447
Ying Xu, Han-Ting Zhang, and James M. O'Donnell	

**Therapeutic Potential of Phosphodiesterase Inhibitors
in Parasitic Diseases 487**
Yasmin Shakur, Harry P. de Koning, Hengming Ke, Junichi Kambayashi,
and Thomas Seebeck

Index 511